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Neural circuitry and immunity
Valentin A. Pavlov1,* and Kevin J. Tracey1,*
1Center for Biomedical Science, The Feinstein Institute for Medical Research, 350 Community Dr, 
Manhasset, NY 11030, USA
Abstract
Research during the last decade has significantly advanced our understanding of the molecular 
mechanisms at the interface between the nervous system and the immune system. Insight into 
bidirectional neuroimmune communication has characterized the nervous system as an important 
partner of the immune system in the regulation of inflammation. Neuronal pathways, including the 
vagus nerve-based inflammatory reflex are physiological regulators of immune function and 
inflammation. In parallel, neuronal function is altered in conditions characterized by immune 
dysregulation and inflammation. Here, we review these regulatory mechanisms and describe the 
neural circuitry modulating immunity. Understanding these mechanisms reveals possibilities to 
use targeted neuromodulation as a therapeutic approach for inflammatory and autoimmune 
disorders. These findings and current clinical exploration of neuromodulation in the treatment of 
inflammatory diseases defines the emerging field of Bioelectronic Medicine.
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1. Introduction
The more we know about the molecular mechanisms of disease, the better therapeutic 
approaches we can design to treat and potentially cure it. This is one of the main principles 
of clinically oriented research, which has led to successful treatments of many disorders. 
Still, there are numerous diseases with no adequate treatments despite serious research 
efforts, employing state of the art technology, to identify new molecular therapeutic targets. 
There are several reasons for this failure to successfully translate research discoveries into 
the clinic, including the complexity of mechanisms regulating these targets within the scope 
of major biological events and the alteration and dysfunction of these regulatory 
mechanisms in disease settings. While this may sound trivial to many and the need for new 
multidisciplinary approaches seems obvious, the path forward is not always clear.
Here we outline important aspects of research performed on crossroads between 
neuroscience and immunology, which holds a great promise to significantly advance the 
treatment of a broad spectrum of diseases characterized by immune dysfunction. This work 
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has provided important insight into the role of neurons as partners of immune cells in the 
regulation of inflammation, which has significant implications in disease pathogenesis. It 
has now become clear that neurons sense inflammatory products and that neuronal activity is 
modulated in inflammatory conditions. Moreover, neurons can detect molecules associated 
with pathogen invasion simultaneously, or even before immune cells [1]. The nervous 
system is positioned to mount fast and directed responses to inflammatory stimuli through 
reflex-like mechanisms and to regulate immune function and inflammation [2–4]. These 
neuron-immune cell interactions can be exploited therapeutically in inflammatory and 
autoimmune conditions, obesity-driven disorders and other diseases characterized by 
aberrant inflammation [5,6]. A growing body of mechanistic insight into the pathways and 
mechanisms at the interface of the nervous system and the immune system has also led to a 
major conceptual switch in designing therapeutic approaches. These new concepts within 
the scope of the emerging field of Bioelectronic Medicine explore selective 
neuromodulation directed to specific molecular targets in disease treatment. Although this 
field is in its infancy, device-generated modulation of vagus nerve activity has already 
started yielding successful translational applications in human disease [7].
2. Nervous system and immune system features favoring interaction and 
loci of neuroimmune communication
The nervous and the immune systems evolved to respond to external and internal stimuli. 
The nervous system integrates physiological processes and controls homeostasis through 
neuronal networks. The immune system provides defense responses against infection and 
injury through immunity. A long history of mutual disregard between Neuroscience and 
Immunology has been followed by research bridging the two disciplines and demonstrating 
a variety of neuro-immune interactions.
2.1. The nervous system flexible authority
The nervous system regulates a broad spectrum of physiological processes. Constant 
communication between physiological systems operating in peripheral (abdominal and 
thoracic) organs and the brain mediates this regulation. A significant part of this 
communication is based on neural reflex mechanisms such as the neural regulation of blood 
pressure and gastrointestinal function and takes place through the neurons of the autonomic 
nervous system. The vagus nerve is a major constituent of the parasympathetic division of 
the autonomic nervous system. This nerve contains afferent (or sensory) fibers that are 
specialized in transmitting signals from peripheral organs to the brainstem, and efferent (or 
motor) fibers that originate in the brainstem medulla oblongata, innervate major peripheral 
organs, and control heart rate, gastrointestinal motility and other vital physiological 
functions [6]. Neural networks involving higher, forebrain re[8]gions also participate in the 
coordinated neural regulation of physiological functions. Vagus and brain neuronal activity 
is constantly modulated in response to peripheral physiological alterations and their 
deviations in disease settings. These peripheral alterations also trigger brain-derived 
responses to maintain homeostasis.
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2.2. The immune complex defense
The immune system detects pathogen invasion, tissue injury or self danger signals, mounts 
responses to contain, neutralize and eliminate these potentially damaging stimuli and forms 
an immunological memory that facilitates this defense strategy upon encountering similar 
challenges in the future. These complex regulatory processes represent immunity. 
Leukocyte/neutrophil and monocyte migration to the site of injury or infection is an early 
and important event in the immune defense repertoire [9]. Pathogen fragments and 
molecules associated with tissue injury interact with molecular sensors, including toll-like 
receptors (TLRs), NOD-like receptors (NLRs) and other pattern recognition receptors on the 
cell surface or in the cytoplasm of macrophages and other innate immune cells. These 
interactions trigger immune cell activation through intracellular cascade mechanisms, 
resulting in activation of NF-κB and other transcription factors with the release of cytokines 
including TNF, IL-1β, IL-6, and HMGB1. In addition to cytokines, the release of other 
inflammatory molecules such as prostaglandins and leukotrienes mediates inflammation, 
which is aimed at neutralizing the invading pathogen and tissue repair. Macrophages and 
dendritic cells also are antigen-presenting cells, linking innate immune factors with adaptive 
immunity, characterized by T and B cell responses, which also contribute to containing the 
inciting stimulus and forming an immunological memory. The release of cytokines is 
essential in inflammation, which normally is localized and timely resolved. The resolution 
of inflammation is an active process guided by molecular mediators collectively termed 
resolvins and protectins, and aimed at restraining leukocyte infiltration and activation 
phagocytosis of pathogen fragments by macrophages [9–11]. However, due to 
circumstances that are not yet well understood, inflammation resolution might be 
compromised and the inflammatory response might become systemic and chronic with 
deleterious consequences. There are various pathophysiological scenarios in which 
excessive release of TNF and other pro-inflammatory cytokines in the circulation mediates 
secondary tissue damage that can be debilitating or lethal. Persistent, non-resolving chronic 
inflammatory responses are implicated in the pathology of several disorders, including 
sepsis, rheumatoid arthritis, inflammatory bowel disease, cardiovascular disease, the 
metabolic syndrome and diabetes.
In the brain, inflammation is predominantly mediated by two types of cells with immune 
function - microglia and astrocytes [12,13]. At physiological conditions these cells are 
important modulators of neuronal structure and function; they play a role in neurogenesis, 
synaptic formation, plasticity and remodeling through the release neurotrophins and 
complement neurotransmission through the release of gliotransmitters [12–15]. Astrocytes 
also are important constituents of the blood brain barrier [13]. Microglia provide immune 
surveillance in the CNS/brain [12,13]. Immune activation in the CNS and the brain in 
particular occurs through mechanisms similar to peripheral innate immune activation [14]. 
Brain infection, brain injury, and neurodegenerative processes trigger microglia activation 
through TLRs and other pattern recognition receptor-mediated signaling with the release of 
TNF, IL-1β, IL-6, reactive oxygen species and other pro-inflammatory molecules, which 
mediate neuroinflammation [14,16,17]. Astrocyte activation with the release of 
inflammatory mediators also contributes to inflammation in the brain [13]. These brain 
immune responses and inflammation are directed towards repair and restoration of neuronal 
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integrity and function. However, chronic neuroinflammation exacerbates neuronal damage, 
associated with further neuronal dysfunction [12,17].
2.3. The neuroimmune common ground
Neurons and immune cells interact with each other. Cooperation between neurons and innate 
immune defense mechanisms is in play even in invertebrates where the immune system and 
the nervous system have their phylogenetic origins. The simple nervous system of 
Caenorhabditis elegans, with 302 neurons – contains neurons specialized in controlling a 
noncanonical unfolded protein response pathway required for innate immunity in this soil 
nematode [18]. Specific aspects of neuron-immune cell interactions in the periphery and in 
the CNS have been actively studied. In the periphery these interactions have been 
highlighted in neurogenic inflammation [19]. In this scenario somatosensory neurons 
(neuroceptors) detect cytokines and other inflammatory products from activated immune 
cells in response to bacterial invasion and mediate inflammatory pain. In addition, these 
neurons - in an antidromic fashion- release substance P and other mediators, which cause 
vasodilation by acting on endothelial and smooth muscle cells, and serve as immune cell 
attractants and activators of immune cells, including dendritic cells, mast cells and T 
lymphocytes [19]. These neuro-immune interactions mediate integrated protective 
mechanisms. However, constant amplification of neurogenic inflammation may have 
implications in the pathogenesis of autoimmune diseases and allergic conditions [19]. 
Important insight into the role of neurons in sensing pathogen-associated molecules was 
provided by Clifford Woolf and colleagues. They have recently found that the presence of 
bacterial (S. aureus) infection activates neuroceptors without triggering innate and adaptive 
immune activation as a mediating event, because it does not involve neutrophils, monocytes, 
T cells, B cells and signaling through TLR2 and MyD88 [1]. Instead, S. aureus activates 
these sensory neurons though induction of calcium flux and action potentials in a direct 
manner through the release of N-formyl peptides and the pore-forming toxin alpha-
hemolysin. In addition, these sensory neurons release neuropeptides that inhibit innate 
immune activation within an axon-reflex mechanism [1]. Specific nociceptor ablation 
abrogates pain sensation, which is also associated with increased local inflammation and 
lymphadenopathy, indicating a tonic anti-inflammatory role of these reflex mechanisms [1]. 
In the CNS/brain, microglial activation and astrogliosis mediate neuroinflammation. 
Persistent brain inflammatory responses have been associated with promoting 
neurodegeneration and contributing to neuronal dysfunction in the context of Alzheimer’s 
disease, multiple sclerosis, Parkinson’s disease, and the sequelae of traumatic brain injury 
and stroke [20].
3. Bidirectional immune-brain communication and the emergence of the 
reflex concept
A neuro-immune dialog bridging the brain and the immune system also takes place. 
Peripheral immune cell activation with the release of cytokines and other immune molecules 
is communicated to the brain through neural and humoral mechanisms and triggers brain-
derived immunoregulatory output through neural and neurohormonal pathways [2,6,21–25]. 
Infiltration of immune cells, including monocytes, T cells, and neutrophils in the brain has 
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also been described [25]. Linda Watkins and colleagues have demonstrated an important 
role of afferent vagus neurons in immune-to-brain communication [26]. Cytokines and other 
inflammatory molecules interact with afferent vagus neurons transmitting the signals to the 
nucleus tractus solitarius (NTS) in the brainstem, where these signals are integrated with 
efferent vagus nerve signaling through neurons residing in the dorsal motor nucleus of the 
vagus (DMN) [8] (Fig. 1). Efferent vagus nerve cholinergic signaling provides a conduit of 
brain-to-immune communication for inhibition of excessive release of TNF and other pro-
inflammatory cytokines [27]. This neuronal circuit is termed “the cholinergic anti-
inflammatory pathway” [27] (Fig. 1). This discovery has been shortly followed by the 
identification of a specific receptor on macrophages and other immune cells - the alpha7 
nicotinic acetylcholine receptor (α7nAChR), as a mediator of anti-inflammatory cholinergic 
output [28]. Together these findings defined a new physiological immunoregulatory 
mechanism - the inflammatory reflex. [2] (Fig. 1). Afferent and efferent vagus nerve fibers 
within the inflammatory reflex provide a physiological interface between the immune 
system and the brain, for communication and control of excessive pro-inflammatory 
signaling. Recent developments in our understanding of the inflammatory reflex have 
highlighted that the efferent vagus nerve communicates with the splenic nerve to suppress 
excessive pro-inflammatory cytokine responses and inflammation [29–31] (Fig. 1). 
Although splenic nerve fibers are catecholaminergic, vagus nerve stimulation results in 
increased levels of acetylcholine in spleen, and vagotomy or splenic nerve transection 
decreases it [32]. Insight into this interesting phenomenon has revealed that a subset of 
splenic T cells, which contain functional choline acetyltransferase, is a source of 
acetylcholine in spleen with a mediating role in the inflammatory reflex [31]. This 
acetylcholine, released under vagus nerve control, mediated through splenic nerve 
catecholaminergic output, interacts with α7nAChR on macrophages and other immune cells. 
This interaction causes suppression of macrophage activation and results in lower TNF and 
other pro-inflammatory cytokine release via intracellular mechanisms, involving suppression 
of NF-κB nuclear translocation. The vagus nerve-based inflammatory reflex is a 
prototypical mechanism of neuroimmunomodulation in the context of physiological reflex 
regulation. Ongoing work has identified other neurons and circuits that regulate immune 
function. For instance, a neural mechanism controlling autoreactive T cell access to the CNS 
of mice with autoimmune encephalomyelitis has been recently demonstrated [33]. In this 
animal model of multiple sclerosis, dorsal vessels of the L5 spinal cord have been identified 
as an entry point for pathogenic CD4+ T cells to enter the CNS [33]. A complex interaction 
among sensory neurons innervating the soleus muscles and catecholaminergic (sympathetic) 
output activates an IL-6-mediated inflammatory amplification in endothelial cells with 
increased generation of chemokines, which facilitates T cell entry into the CNS [33,34]. 
Another study has demonstrated the critical importance of neural mechanisms in 
immunosuppression after stroke and the specific role of catecholaminergic modulation of 
hepatic invariant NKT cells as a central event in this context, and has suggested implications 
of neural circuitry in pneumonia development and mortality after stroke [35]. 
Catecholaminergic signaling was also recently implicated in a neural circuit controlling 
lymphocyte trafficking [36]. Neuronal catecholaminergic output, mediated through 
lymphocyte β2 receptor signaling, which is associated with chemokine receptors suppresses 
lymphocyte egress from lymph nodes. The physiological importance of this neural 
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mechanism, which reduces lymphocyte recruitment into peripheral tissues is related to 
suppression of T cell mediated tissue damage [37,38]. These reports highlighted the broader 
scope of neural circuitry that is organized in a reflex manner in controlling immunity by 
regulating a variety of immune responses at different anatomical locations [4,5].
4. A close look at the efferent vagus nerve immunoregulatory circuitry
Research during the last 10–15 years utilizing vagus nerve stimulation, surgical transection 
of the vagus nerve (vagotomy) and state-of-the-art genetic, pharmacological and 
immunological methodology generated abundant mechanistic insight into vagus nerve 
neurocircuitry implicated in immune regulation and the neurophysiology of the 
inflammatory reflex.
4.1. Vagus nerve stimulation
Electrical cervical vagus nerve stimulation (VNS) has been instrumental for demonstrating 
the efficacy of efferent vagus nerve signaling in suppressing serum and hepatic TNF and 
other pro-inflammatory cytokine levels and attenuating systemic endotoxemic shock [27]. 
Acetylcholine, an important mediator of efferent vagus nerve signaling has been found to 
suppress endotoxin-stimulated macrophage release of TNF, IL-1β, IL-6 and IL-18 [27]. 
These discoveries have led to numerous subsequent studies that have elucidated 
immunoregulatory vagus nerve signaling in various conditions. In rats with acute 
hypovolemic hemorrhagic shock and systemic inflammation, VNS suppresses serum TNF, 
hepatic TNF gene expression and hepatic NF-κB activation by blocking IκB degradation; 
these effects parallel alleviated hypotension and an increased survival time [39]. In murine 
postoperative ileus, VNS suppresses intestinal muscle layer resident macrophage activation 
and alleviates the condition [40]. Activation of the signal transducer and activator of 
transcription (STAT) in intestinal macrophages was shown to play a role in mediating VNS 
effects in this context [40]. VNS suppresses leukocyte trafficking to a subcutaneous site of 
inflammation, a finding implicating vagus nerve circuitry in the regulation of leukocyte 
migration across the endothelium during local inflammation [41]. A very recent study 
reported that single pulse low frequency VNS stimulation is sufficient to suppress TNF 
release in endotoxemia [42]. This finding is important because it suggests further 
exploration of a very short duration of VNS in a broader scope of inflammatory conditions, 
including asthma, where continuous VNS should be avoided because of potential 
bronchoconstriction effects. In addition to efferent signals, the activation of afferent vagus 
nerve signaling contributes to anti-inflammatory effects, an observation suggesting that VNS 
may trigger brain-derived immunoregulatory output [42]. VNS also suppresses peripheral 
hemorrhage, which suggests important therapeutic implications of VNS in preventing 
uncontrolled bleeding [43]. In addition to electrical VNS, transcutaneous vagus nerve 
stimulation suppresses serum TNF levels in murine endotoxemia [44]. The efficacy of this 
approach of VNS has been shown in preclinical settings of sepsis, a notorious clinical 
syndrome that is characterized by dysregulation of immune and other physiological 
responses and which is the number one killer in the ICUs. VNS initiated in a clinically-
relevant time frame – 24 hours after the onset of cecal ligation and puncture-induced murine 
sepsis significantly suppresses serum levels of HMGB1 - a pro-inflammatory molecule and 
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a pivotal cytokine mediator of sepsis lethality and improves survival [44]. VNS by 
implanted device-generated electrical stimulation at relatively high frequency is clinically 
approved for the treatment of epilepsy and pharmacoresistant depression [45]. In addition to 
acute settings, recent studies have evaluated the efficacy of VNS generated by implanted 
devices in murine models of chronic inflammatory disease. Low frequency VNS through 
implanted cuff electrode (once daily for 7 days) significantly alleviates the disease score, 
inflammation and other underlying pathology in rats with collagen-induced arthritis [46]. 
Implanted VNS (3 hours of stimulation per day for 5 days) in freely moving rats 
significantly alleviates colonic inflammation and severity of colitis [47]. These studies with 
implanted VNS in animals with chronic inflammatory conditions have paved the path to 
ongoing clinical trials in patients with rheumatoid arthritis and inflammatory bowel disease.
4.2. Vagotomy
In contrast to VNS, interruption of vagus nerve signaling through vagotomy results in higher 
pro-inflammatory cytokine levels in endotoxemic animals, pointing to a tonic anti-
inflammatory role of the vagus nerve [27]. Cervical bilateral vagotomy provides an 
approach for a total interruption of vagus nerve signaling. However, it is associated with 
high lethality, which limits the use of this approach to acute experiments with anesthetized 
animals. Therefore, bilateral subdiaphragmatic vagotomy and unilateral cervical vagotomy 
have also been explored in inflammatory settings. For instance, bilateral subdiaphragmatic 
vagotomy prior to dextran sodium sulfate (DSS)-induced murine colitis results in higher 
colonic levels of TNF and other pro-inflammatory cytokines, increased disease activity 
indices and elevated macroscopic and histological scores as compared to sham-operated 
mice [48]. Vagotomy does not alter disease severity in M-CSF-deficient mice, which 
indicates a role for macrophages in mediating these vagus nerve effects [48]. The disease-
exacerbating effect of subdiaphragmatic vagotomy in a DSS-induced model of colitis has 
been recently confirmed and associated with decreased acetylcholine levels in spleen in 
vagotomized animals [32]. Subdiaphragmatic vagotomy also increases serum pro-
inflammatory cytokine levels and worsens the disease severity in a dog model of acute 
necrotizing pancreatitis, thus indicating a tonic suppressive role of the vagus nerve in the 
regulation of pancreatitis inflammation and severity [49]. Moreover, unilateral cervical 
vagotomy results in exacerbated pancreatic damage and increased systemic IL-6 levels in a 
mouse model of cerulean-induced pancreatitis [50]. Unilateral cervical vagotomy 
exacerbates the inflammatory response manifested by increased plasma and cardiac TNF 
and IL-1β levels in endotoxemic rats [51]. This approach results in a decreased survival rate 
in mice with E. coli pneumonia [52]. Unilateral cervical vagotomy has been instrumental in 
making the discovery by Charles Serhan and colleagues that the vagus nerve controls the 
resolution of inflammation [11]. Vagotomy results in lower lung and peritoneum gene and 
protein expression of the axon guidance molecule netrin-1, which is an important 
endogenous pro-resolution molecule in zymosan-induced peritonitis [11]. In addition to 
decreased neutrin-1 levels, vagotomy is associated with lower acetylcholine levels, higher 
TNF, IL-1β, IL-6, HMGB1, MIP-1α, and KC, and higher leukocyte numbers in 
inflammatory exudates. These and additional observations indicate that vagus nerve 
signaling regulates a bidirectional synergistic interaction between netrin-1 and other 
resolvins, including resolvin D1 to decrease leukocyte migration and stimulate macrophage 
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phagocytosis in facilitating inflammation resolution. These findings importantly broaden the 
scope of implications of vagus nerve signaling in the regulation of inflammation.
4.3. The vagus nerve - splenic nerve partnership in the inflammatory reflex
The anti-inflammatory effects of VNS are linked to suppression of TNF in the spleen, the 
organ with a major contribution to systemic TNF during endotoxemia [29,30]. These effects 
require an interaction between the vagus nerve and the splenic nerve in the efferent arm of 
the inflammatory reflex (Fig. 1). Neuroanatomical findings have pointed to the celiac plexus 
as an important site of vagus nerve–splenic nerve communication. Efferent vagus nerve 
fibers through abdominal subdiaphragmatic anterior and posterior branches innervate the 
celiac ganglia and the superior mesenteric ganglion in the celiac plexus [53,54]. Recently, 
by utilizing double-labeling for tyrosine hydroxylase and vesicular acetylcholine transporter 
(VACh), Hoover and colleagues have demonstrated that cholinergic VAChT-positive nerve 
fibers surround abundant neuronal populations with catecholaminergic phenotype in the 
celiac ganglia and the superior mesenteric ganglion of mice [55]. These ganglia are a major 
source of spleen-projecting catecholaminergic fibers [56–58]. Accordingly, carefully 
performed transection of the multiple nerve fibers within the splenic nerve (splenic 
neurectomy) abolishes the anti-inflammatory effect of VNS [30]. Catecholaminergic nerve 
endings in spleen are in proximity of splenic lymphocytes, including T cells, which contain 
choline acetyltransferase (ChAT), the acetylcholine biosynthesizing enzyme [31]. VNS 
results in increased acetylcholine release in spleen and this effect is mediated through 
splenic nerve catecholaminergic signaling acting on lymphocytes. VNS does not suppress 
TNF levels in nude mice, indicating that lymphocytes are required [31]. Passive adoptive 
transfer of ChAT-T lymphocytes into nude mice restores the anti-inflammatory efficacy of 
VNS, which demonstrates that these acetylcholine-producing cells are necessary [31]. 
Consequently, acetylcholine acts on the α7 nAChRs on macrophages in the spleen and 
suppresses TNF production. Vagus nerve–splenic nerve signaling is implicated in the 
regulation of adaptive immune responses [59]. VNS in Streptococcus pneumonia suppresses 
the normal migration of B cells to the splenic red pulp, where they become antibody-
secreting cells, by retaining the cells in the marginal zone, and decreases B cell antibody 
production. Splenic nerve transection significantly abolishes the migration arrest and results 
in reorganization of lymphoid architecture [59]. These and other studies in the context of 
endotoxemia, sepsis, inflammatory bowel disease [29,30,32] and other inflammatory 
conditions have triggered a great deal of interest in the vagus nerve-splenic nerve signaling 
in immune regulation. Of note, a study has questioned the vagus nerve-splenic nerve 
interaction [60]. Based on a single approach – injection of a retrograde tracer, the suprarenal 
ganglia were indicated as the main source of spleen-projecting neurons [60]. In addition, no 
labeled neurons in the right celiac ganglion and only a small percentage of these neurons in 
the left celiac ganglion were found [60]. No labeled neurons were reported in “superior 
mesenteric ganglia of either side” [60], a puzzling anatomical designation, considering the 
fact that the superior mesenteric ganglion is a single formation in a very close proximity to 
the left celiac ganglion and a part of the celiac-mesenteric ganglionic complex [53–55]. 
These observations are in clear contrast with other previous studies, utilizing a variety of 
approaches to identify the celiac ganglia and the superior mesenteric ganglion as the source 
of spleen-projecting catecholaminergic fibers [56–58]. The superior mesenteric-celiac 
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ganglia have been demonstrated as the site of origin of catecholaminergic/noradrenergic 
innervations of the rat spleen by using selective ganglionectomy and retrograde tracing 
combined with immunocytochemical localization of tyrosine hydroxylase [57]. 
Simultaneously, the celiac-mesenteric gangla have been characterized as a major source of 
efferent innervations to the spleen in rats by using retrograde tracing, splenic nerve 
transection and catecholamine histofluorescence in the spleen [56]. The celiac ganglia as a 
supplier of splenic catecholaminergic innervations has been further demonstrated by using 
selective celiac ganglionectomy, tyrosine hydroxylase immunohystochemistry and 
norepinephrine determination [58]. Surprisingly, the authors of this study [60] do not 
comment on the apparent discrepancy between their observations and these previously 
published findings [56–58]. Instead, they focus on determining the effect of VNS on the 
electrical activity of suprarenal ganglia neurons to conclude that there is no effect. They also 
record whole splenic nerve activity and examine the effect of VNS on it and propose that 
activation of efferent vagus nerve signaling does not alter splenic nerve activity [60]. As 
previously demonstrated, splenic nerve catecholaminergic fibers innervate splenic capsule, 
trabeculae, vasculature, and parenchyma [57]. In addition to vasomotor fibers, whose 
activity is usually recorded there are other catecholaminergic fibers branching in the 
parenchyma and associated with T cell and other immune cell interactions [31,61–63]. The 
lack of adequate methodological description of splenic nerve isolation and recording in this 
study [60] makes it virtually impossible to assess what splenic neuron activity was recorded. 
A preponderance of data indicates the importance of efferent vagus nerve-splenic nerve 
functional integrity in controling spleen pro-inflammatory cytokine production [29–32].
4.4. The interface with, and within the immune component
α7nAChR is an important receptor mediator in the neural vagus nerve control of immune 
function. This role of the α7nAChR was initially indicated by the observation that in 
contrast to its suppressive effect in wild type (WT) mice, VNS does not significantly alter 
TNF levels in α7nAChR KO mice during endotoxemia [28]. In addition, treatment with the 
centrally-acting acetylcholinesterase inhibitor galantamine, whose brain-mediated mode of 
anti-inflammatory activity requires an intact vagus nerve as a brain-to periphery conduit, 
also fails to inhibit systemic TNF levels in endotoxemic α7nAChR KO mice [64]. The 
classical neuronal homeopentameric α7nAChR is expressed in the brain and the presence of 
α7 subunit containing forms of the receptor has been reported in peripheral autonomic 
ganglia and immune cells. Experimental evidence has attributed the cellular origin of the 
α7nAChR with a role in mediating cholinergic anti-inflammatory output to immune cells. 
For instance, the release of pro-inflammatory cytokines by macrophages from α7nAChR 
KO mice or macrophages with α7nAChR anti-sense downregulation is not affected by 
cholinergic stimulation [28]. Furthermore, α7nAChR deficiency in the immune system 
generated by adoptive transfer of α7nAChR KO bone marrow cells to irradiated WT mice, 
abolishes VNS inhibition of serum TNF levels during endotoxemia while α7nAChR 
neuronal deficiency by transferring WT bone marrow cells to irradiated alpha7 KO mice 
does not alter this VNS anti-inflammatory effect [65]. This mechanistic insight has allowed 
studying the anti-inflammatory efficacy of small molecule α7nAChR agonists at various 
inflammatory conditions. GTS-21 was the first selective α7nAChR agonist whose anti-
inflammatory properties were demonstrated in murine models of pancreatitis [50], 
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endotoxemia and severe sepsis [66]. Importantly, treatment with GTS-21 initiated within a 
clinically relevant time frame (24 hours after the onset of severe sepsis), significantly 
improves survival and lowers serum levels of HMGB1, a late mediator of the disease [66]. 
Another selective endogenous α7nAChR agonist is choline, a byproduct of acetylcholine 
degradation. Choline suppresses serum TNF and HMGB1, and improves survival in 
endotoxemia and experimental sepsis in a clinically-relevant time frame [67]. The anti-
inflammatory effects of choline are mediated through α7nAChR-signaling, as demonstrated 
by using α7nAChR KO mice [67]. Several other studies have evaluated anti-inflammatory 
efficacy of α7nAChR agonists in endotoxemia, sepsis, rheumatoid arthritis, mechanical 
ventilation-induced lung injury, postoperative neuroinflammation, ischemia-reperfusion 
injury and other inflammatory conditions [68–71]. These studies have also contributed to 
delineating intracellular mechanisms downstream of the α7nAChR with a role in inhibiting 
TNF and other pro-inflammatory cytokine production. These mechanisms involve inhibition 
of the nuclear translocation of the transcription factor NF-κB [21,66,67,72] and activation of 
the JAK2-STAT-3 pathway [40]. In addition to triggering anti-inflammatory signal 
transduction through activation of the α7nAChR on the immune cell surface, a very recent 
report has revealed a role for cholinergic activation of the α7nAChR expressed on the 
mitochondrial membrane in immune regulation through inhibition of the inflammasome 
[73]. Immune cell activation is accompanied by intracellular accumulation of acetylcholine, 
which interacts with the mitochondrial α7nAChR resulting in stabilization of mitochondrial 
membrane permeability, preventing mitochondrial DNA release and consequently, 
inhibition of the NLRP3 inflammasome activation [73].
5. The remote immunomodulatory switches in the brain
The brain is an active participant in the regulation of immunity; it receives and integrates 
signals for altered immune homeostasis and mounts responses to control peripheral immune 
function through the inflammatory reflex and other pathways. We have begun to reveal the 
neuromodulatory and neuroreceptor mechanisms with a role in this regulation and evaluate 
therapeutic anti-inflammatory approaches based on brain cholinergic activation.
5.1. Relevant brain neuroanatomical organization
Neuronal interactions between the NTS, DMN and area postrema within the dorsal vagal 
complex integrate the vagus nerve-based inflammatory reflex at the level of the brainstem 
(Fig. 1). The dorsal vagal complex is interconnected with the hypothalamus, thalamus, 
hippocampus, amygdala, medial prefrontal and other cortex regions. These reciprocal 
circuits provide neuroanatomical and functional substrates for modulation of vagus nerve 
activity and the inflammatory reflex, and intersection with brain networks associated with 
behavioral, endocrine and metabolic regulation [6,74]. Experimental evidence indicates a 
role for cholinergic signaling in the brain modulation of the inflammatory reflex. The brain 
cholinergic system is a major neuromodulatory system with widespread innervations, 
originating from two major locations, the basal forebrain and the mesopontine tegmentum 
[75,76]. Basal forebrain cholinergic pathways predominantly innervate the cortex 
(neocortex), hippocampus, olfactory bulb and amygdale [75,76]. Cholinergic innervations 
from the mesopontine pedunculopontine tegmental and laterodorsal tegmental nuclei 
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innervate, among other brain regions, the thalamus, hypothalamus and cerebellum [75,76]. 
Acetylcholine, released from cholinergic axons interacts with two types of receptors on 
cholinoceptive neurons; muscarinic M1 through M5 subtypes of metabotropic, G protein-
coupled receptors and nicotinic ionotropic receptors. Muscarinic acetylcholine receptors 
(mAChRs) and specifically the M1 subtype play a major role in processing cholinergic 
transmission in the brain [77]. The cortex, hippocampus, hypothalamus and other brain areas 
innervated by cholinergic pathways interact directly or through multisynaptic pathways with 
the dorsal motor complex, the brainstem integrative center of the inflammatory reflex 
[6,74,78–80].
5.2. Brain muscarinic receptor–mediated networks regulate peripheral inflammatory 
responses
Brain mAChR subtypes have different synaptic locations and function in cholinergic 
transmission. The M1 mAChR is predominantly postsynaptic on cholinoceptive neurons in 
the cortex, hippocampus and other brain areas. The M2 mAChR is mostly presynaptic and 
its role in the cholinergic synapse is inhibition (autoinhibition) of acetylcholine release. 
Central, intracerebroventricular administration of an M1 mAChR agonist or a M2 mAChR 
antagonist significantly suppresses serum TNF levels in endotoxemic animals [81]. Central 
mAChR ligand administration also significantly increases efferent vagus nerve activity 
indicated by activation of the high frequency component of heart rate variability based on 
ECG analysis [81]. These observations have provided experimental evidence for a role of 
brain mAChR- mediated cholinergic signaling in the regulation of peripheral inflammation 
through functional integration with efferent vagus nerve activity (Fig. 1). They also suggest 
that brain mAChR signaling may mediate the previously demonstrated central activation of 
the cholinergic anti-inflammatory pathway by the anti-inflammatory compound CNI-1493 
[82], identified as a mAChR ligand. Central administration of the M1 mAChR McN-A-343 
and the M2 mAChR antagonist methoctramine have recently been shown to inhibit colonic 
TNF, IL-6 and other pro-inflammatory cytokines and alleviate disease severity in two 
models of colitis [32,83]. Increased acetylcholine levels in spleen of mice treated with McN-
A-343 mediate anti-inflammatory drug efficacy in colitis and these effects require signaling 
along the vagus nerve and splenic nerve, because they are abolished in mice with vagotomy 
and splenic nerve transection [32]. An anti-inflammatory role of brain mAChRs has been 
demonstrated in experimental models of hemorrhagic shock [84,85] and in mediating the 
anti-inflammatory efficacy of acupuncture [86]. In addition, peripheral administration of the 
centrally-acting M1 mAChR agonist xanomeline significantly suppresses serum TNF and 
improves survival in murine endotoxemia [87]. Anti-inflammatory effects of xanomeline are 
mediated through brain mAChRs and require an intact vagus nerve-splenic nerve axis [87]. 
Interestingly, xanomeline provides a long-lasting anti-inflammatory protection, indicated by 
the observation that drug administration as early as 20 hours prior to LPS is efficient in 
suppressing serum TNF levels and improving survival in endotoxemic mice [87]. This long-
lasting drug efficacy is associated with alterations in splenic leukocyte subpopulations 
including a proportional increase in T cell numbers in parallel with reduced splenocyte 
responsiveness to inflammatory stimulation. In addition, current studies indicate that 
peripheral administration of a centrally-acting compound, which belongs to the latest 
generation of positive allosteric modulators of the M1 mAChRs suppresses pro-
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inflammatory cytokine levels in endotoxemia and improves survival in endotoxemia and 
severe sepsis (unpublished data). Preclinical development of xanomeline and this latest 
generation of compounds has been mainly driven by the search for mAChR ligands that are 
more efficient and devoid of side effects in the context of Alzheimer’s disease and 
schizophrenia [88–92]. Xanomeline treatment of patients with schizophrenia significantly 
alleviates positive and negative symptoms and cognitive deterioration [90]. Peripheral 
inflammation reported in the context of schizophrenia has been proposed to have a causative 
role in disease pathology [93,94]. In light of ameliorating peripheral inflammation by 
xanomeline [87], one may now ask the intriguing question of whether anti-inflammatory 
effects of xanomeline contribute to its efficacy in clinical settings of schizophrenia. In 
contrast to centrally-acting cholinergic modalities, anticholinergic drugs, which are 
frequently prescribed to elderly have been associated with exacerbated inflammatory 
responses to endotoxemia in a neurodegenerative tauopathy murine model [95,96]. 
Importantly, an increase in IL-1β expression in spleen and brain is significantly more 
pronounced in endotoxemic mice pretreated with trihexyphenidyl - a centrally-acting M1 
mAChR antagonist as compared with another compound with a weaker CNS activity [95]. 
These findings suggest that inhibition of brain cholinergic M1 mAChR signaling 
exacerbates inflammation. It is interesting and potentially important that while modulation 
of brain mAChRs and specifically activation of the M1 subtype have been linked to anti-
inflammatory effects, cholinergic activation through peripheral mAChR-mediated 
mechanisms has been associated with pro-inflammatory effects as demonstrated in patients 
with irritable bowel syndrome [97]. In addition, Kawashima and colleagues have shown that 
genetic ablation of both M1 and M5 mAChRs results in lower levels of TNF and IL-6 
released by splenic mononuclear leucocytes incubated with ovalbumin, suggesting a tonic 
pro-inflammatory role of these receptors [98].
5.3. Borrowing from Alzheimer’s disease drugs to study inflammation: 
acetylcholinesterase inhibitors as anti-inflammatory agents
Diminished acetylcholine release in the brain due to neurodegeneration involving basal 
forebrain cholinergic neurons is an important pathophysiological feature in Alzheimer’s 
disease. Accordingly, the current treatment of cognitive deterioration associated with 
Alzheimer’s disease is largely based on the use of centrally-acting acetylcholinesterase 
inhibitors, which inhibit acetylcholine breakdown, thus potentiating brain cholinergic 
signaling. These drugs also have powerfull anti-inflammatory properties. Central cholinergic 
activation by peripheral administration of the centrally-acting AChE inhibitors galantamine 
and huperzine-A results in significant inhibition of serum TNF and improved survival in 
endotoxemic mice [64]. The anti-inflammatory effect of galantamine is mediated through 
brain mAChRs, depends on the integrity of the vagus nerve and is abolished in α7nAChR 
KO mice [64]. These findings and the reported stimulation of efferent vagus nerve activity 
by galantamine [99], indicated that CNS mAChR-mediated effects of galantamine are 
functionally linked to activation of the vagus nerve-based cholinergic anti-inflammatory 
pathway (Fig. 1). Interestingly, single dose galantamine administration provides at least a 20 
hours time window of anti-inflammatory protection, in line with a similar long-lasting effect 
of the M1 mAChR agonist xanomeline in endotoxemic mice [87]. Galantamine treatment of 
mice with colitis significantly alleviates colonic inflammation and disease severity, 
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associated with increased acetylcholine release in spleen, interacting with the α7nAChRs on 
dendritic cells [32]. Pharmacological blockade of brain mAChR receptors, vagotomy and 
splenic neurectomy abolish these effects and the increased release of acetylcholine in spleen. 
In addition, vagotomy and splenic neurectomy significantly decreases acetylcholine release 
in spleen. Together these findings indicate that vagus nerve - splenic nerve interaction 
mediates galantamine effects in inflammatory bowel disease [32] (Fig. 1). In addition to 
endotoxemia and inflammatory bowel disease, galantamine exerts anti-inflammatory effects 
and alleviates the disease progression in a rat model of adjuvant-induced arthritis [100]. 
Involvement of brain AChE inhibition and peripheral site AChE inhibition has been 
described in lowering intestinal inflammation by rivastigmine, another centrally-acting 
AChE inhibitor [101]. Several studies further indicate the primary importance of CNS AChE 
inhibition in achieving suppression of inflammation at various inflammatory conditions. For 
instance, treatment with the centrally-acting AChE inhibitor physostigmine results in higher 
level of suppression of the acute colonic inflammatory response in rats with colitis as 
compared to treatment with the peripherally-acting neostigmine [102]. In addition, treatment 
with the peripherally-acting AChE inhibitor neostigmine fails to alleviate organ injury in 
murine endotoxemia [103] and pro-inflammatory cytokine responses associated with 
mechanical ventilation [104]. Very recently, treatment with the centrally-acting AChE 
inhibitor donepezil has been shown to increase vagal tone, suppress plasma TNF, IL-6 and 
IFN-γ levels, attenuate development of hypertension and prevent cardiac remodeling in 
spontaneously hypertensive rats [105]. In contrast, treatment with the peripherally-acting 
AChE inhibitor pyridostigmine fails to suppress plasma pro-inflammatory cytokine levels 
and reduce high blood pressure [105].
Interestingly, in addition to neuroinflammation, increased levels of peripheral inflammation 
have been reported in patients with Alzheimer’s disease, a neurodegenerative disorder 
characteristically affecting basal forebrain cholinergic neurons with a resultant diminished 
acetylcholine release. There are also reports that treatments with AChE inhibitors of patients 
with Alzheimer’s disease result in suppression of peripheral inflammatory responses. For 
instance, treatment of patients with Alzheimer’s disease with the AChE inhibitor donepezil, 
as compared to untreated patients and healthy controls results in lower gene expression and 
protein levels of IL-1β and higher expression and levels of the anti-inflammatory IL-4 in 
both unstimulated and phytohemagglutinin-stimulated peripheral blood mononuclear cells 
[106]. Furthermore, peripheral blood mononuclear cells isolated from Alzheimer’s disease 
patients release higher levels of IL-1β and IL-6 as compared to healthy controls, and 
treatment of these patients with the AChE inhibitor donepezil for one month significantly 
decreases these levels as compared to prior to treatment conditions [107]. An inverse 
correlation between duration of treatment with galantamine, rivastigmine or donepezil of 
patients with Alzheimer’s disease and plasma CRP levels also was reported [108]. These 
findings highlight a correlation between brain cholinergic hypofunction and elevated 
markers of peripheral inflammatory responses in humans. In addition, they suggest that a 
boost in brain cholinergic signaling that compensate for this hypofunction may alleviate 
peripheral inflammation.
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5.4. The “suffering” brain and its cholinergic symptoms in inflammatory and autoimmune 
conditions
Immune cell activation and inflammation in response to infection or injury can cause a 
spectrum of alterations in brain function known as sickness behavior, which is regarded as 
an important adaptive mechanism [23–25] (Fig. 2). These brain alterations occur in parallel 
with activation of brain-derived neural immunoregulatory pathways. Peripheral 
administration of LPS or live bacteria has been instrumental in demonstrating that peripheral 
inflammation causes brain pro-inflammatory signaling [109], which has a mediating role in 
sickness behavior [23,25] (Fig. 2). Increased systemic cytokine levels in endotoxemia are 
associated with activation in pro-inflammatory IL-1β and IL-6 gene expression and 
microglial morphological alterations, indicative for microglia activation as early as 4 hours 
following peripheral endotoxin administration [110]. These pro-inflammatory alterations 
affect the hippocampus, cortex, hypothalamus and other brain areas in a region-specific 
manner with no apparent evidence of neurodegeneration as an underlying event [110]. 
Excessive and non-resolved forms of peripheral inflammation and maladaptive 
transformations of sickness behavior can result in deleterious and life-threatening 
neurological complications described in several conditions with inflammatory and 
autoimmune etiology, including sepsis, chronic liver disease, inflammatory bowel disease, 
rheumatoid arthritis, postoperative conditions and obesity [23,69,111–119] (Fig. 2). Many 
patients with these disorders suffer depression; it is documented that depressive conditions 
exacerbate pro-inflammatory cytokine levels and inflammation, which can affect brain 
neurotransmitter systems and brain function [120]. Studying brain cholinergic signaling in 
the context of neurological complications associated with inflammatory disorders is 
important for several reasons. Brain cholinergic mAChR–mediated signaling regulate long-
term potentiation and neuroplasticity, adult neurogenesis, and cerebral blood flow [76,121]. 
Brain cholinergic pathways are critically implicated in learning, memory, attention, 
conscious awareness, sleep, control of movements and peripheral/visceral function 
[76,77,122]. Many of these functions are impaired in inflammatory conditions (Fig. 2). 
Brain cholinergic mAChR-mediated signaling also has an important role in the regulation of 
peripheral cytokine responses and inflammation [6,32,64]. In addition, experimental 
evidence indicates that brain cholinergic signaling regulates local brain inflammatory 
responses [123–126] and the brain cholinergic system is affected in peripheral inflammatory 
and metabolic conditions [110,127–129]. Sepsis is a lethal disorder with peripheral immune 
and metabolic dysregulation and neuropsychiatric manifestations. This clinical syndrome is 
the most frequent cause of death in the intensive care units [130]. The spectrum of 
pathophysiological brain alterations during sepsis is termed sepsis-associated 
encephalopathy (SAE), or septic encephalopathy, which ranges from delirium to coma 
[114]. SAE can be defined as brain dysfunction, secondary to infection in the body, and no 
CNS infection [114]. Delirium is a neurobehavioral syndrome caused by dysregulation of 
neuronal activity secondary to broad spectrum of systemic disturbances, including increased 
release of pro-inflammatory cytokines and systemic inflammation [114,127,131]. Important 
hallmarks in SAE and delirium are altered neurotransmission and cerebral microcirculation 
[114]. There is experimental evidence for a major role of cholinergic hypofunction in 
delirium [132]. Considering the importance of brain cholinergic signaling in cerebral blood 
flow regulation, attention, memory, sleep and the control of voluntary movements, 
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decreased cholinergic tone can have a profound contribution to SAE. This cholinergic 
hypofunction occurs in parallel, and is interrelated to alterations in other neurotransmitter 
systems, including dopaminergic and catecholaminergic hyperactivity, and fluctuations in 
GABA-ergic and glutamatergic systems [132]. SAE is an early event in sepsis, can be 
developed in upto 80% of the patients and is an independent predictor of mortality and long 
term morbidity. The saga of the patients with sepsis does not end with their discharge from 
the hospital. Long-term cognitive impairment, functional disability and increased mortality 
have been documented in sepsis survivors. Insight into SAE and its long reaching post-
sepsis consequences holds promises for an early diagnosis and adequate treatments, which 
are urgently needed [114]. The pro-inflammatory cytokine HMGB1 was recently identified 
as an important mediator of pathogenesis and cognitive impairment in murine sepsis 
survivors and as a potential therapeutic target [133,134]. Another option to be explored in 
alleviating septic sequelae is the use of galantamine and other AChE inhibitors. These drugs 
are already in clinical use in the treatment of cognitive impairment in patients with 
Alzheimer’s disease and myopathies such as myasthenia gravis, and they have powerful 
anti-inflammatory properties. Another complex and life-threatening neuropsychiatric 
syndrome is hepatic encephalopathy, which occurs in the context of acute and chronic liver 
failure in cirrhosis associated with metabolic and immune dysregulation [116,117]. 
Cognitive impairment, deteriorations in sleep, motor activity and coordination, lethargy, 
confusion, and ultimate progression into coma define the spectrum of hepatic 
encephalopathy [117]. The pathogenesis of hepatic encephalopathy is not well understood. 
Increased ammonia levels are thought to play an important role in astrocyte enlargement and 
dysfunction in the brain in parallel with microglia activation, oxidative stress and increased 
pro-inflammatory cytokine levels [116,117]. Brain cholinergic impairment has also been 
reported in patients with cirrhosis and in models of liver failure [135]. Significant increases 
in postmortem cortex AChE activity in patients with hepatic encephalopathy and cirrhotic 
rats, and a marked decrease in acetylcholine levels in these animals are found [135]. In 
addition, treatment with the centrally-acting AChE inhibitor rivastigmine alleviates memory 
deficits in a model of liver failure [135]. As summarized by Inouye and colleagues, brain 
cholinergic pathways overlap with locations of brain abnormalities and abnormal perfusion 
detected by neuroimaging in patients with hepatic encephalopathy, cardiotomy, and 
traumatic brain injury [132]. Intriguingly, brain cholinergic impairment coexists with lower 
vagal tone in patients with cirrhosis [136,137] and the decrease in vagus nerve activity in 
patients with cirrhosis correlates with the degree of hepatic encephalopathy [137]. These 
findings provide a rationale for further studies exploring the relationship between altered 
brain cholinergic signaling, decreased vagus nerve activity and increased inflammatory 
indices in SAE, hepatic encephalopathy and other inflammatory conditions with a deferent 
degree of brain impairment for evaluating therapeutic interventions. Promising results from 
a very recent clinical trial with rivastigmine in cirrhotic patients with hepatic 
encephalopathy represent one of the first validations of this line of therapeutic explorations 
[138]. Brain pro-inflammatory signaling, cognitive impairment and behavioral deficiencies 
have been described in obesity and type 2 diabetes, diseases with metabolic and 
inflammatory etiology [118,119,139–141] (Fig. 2). An autoimmune disease such as type 1 
diabetes is associated with alterations in brain cholinergic signaling and impaired cognitive 
functions reported in animal models [142,143] and worsened cognitive domains in patients 
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[141]. Another notorious example of an autoimmune disease with characteristic neurological 
complications is systemic lupus erythematosus (Fig. 2). Betty Diamond and colleagues have 
provided important insight into the neurological complications of this autoimmune condition 
pointing to a mediating role of peripheral antibodies targeting the brain glutamatergic 
system [144–147]. These findings have provided a rationale for developing new therapeutic 
modalities.
5.5. Device-generated modulation of brain neurocircuitry as a future anti-inflammatory 
approach
The brain cholinergic system provides widespread innervations to the cortex, other forebrain 
areas, brainstem and cerebellum and controls a variety of brain functions [75,76]. In 
addition, brain cholinergic mAChR mediated signaling plays a role in controlling 
cardiovascular and gastrointestinal function, pancreatic secretion and other peripheral 
physiological processes via vagus nerve mediated mechanisms [85,148–151]. In addition to 
pharmacological modalities cholinergic pathways in the brain can be modulated by using 
electrical or other forms of device-generated output. Device-generated brain modulation, 
including deep brain electrical stimulation, transcranial magnetic stimulation, and 
transcranial direct current stimulation has been in clinical or exploratory use for various 
neurological conditions [152,153]. There is a growing interest in these approaches judging 
by the increasing number of relevant publications as recently summarized [152]. In parallel, 
optogenetic modulation has been actively utilized as a highly selective methodology to 
provide specific mechanistic insight into the physiological role of brain neuronal circuits. 
Electrical and other forms of device-generated output have been currently used in studying 
the role of specific cholinergic pathways in the regulation of inflammation. Identifying brain 
networks with a role in peripheral neuromodulation may indicate future implications of deep 
brain stimulation or other non-invasive approaches in the treatment of inflammatory and 
autoimmune conditions.
6. Neurocircuitry and inflammation in obesity and cancer
The prevalence of obesity and the associated metabolic syndrome has reached epidemic 
proportions. The serious health threat, which obesity and the metabolic syndrome represent, 
is associated with the increased risk of developing type 2 diabetes, cardiovascular disease, 
cancer and other debilitating and life-threatening disorders [154]. The metabolic 
dysregulation in obesity is importantly interrelated with chronic low-grade inflammation as 
major underlying events in insulin resistance, fatty liver disease and other obesity-associated 
complications [6,155–157]. The expanded abdominal adipose tissue, infiltrated with 
macrophages, neutrophils, T cells and other immune cells is considered to be the main 
source of inflammation in obesity [155,156]. In addition to immune cells, enlarged 
adipocytes, which are typically a fat storage, become active cytokine- and adipokine-
producing cells in this microenvironment [156,158]. Dysregulated release of adipokines, 
including leptin, resistin, adiponectin, and TNF, IL-1β, IL-6 and other cytokines mediate 
obesity-associated inflammation [6,155,156,158]. The vagus nerve within reflex 
mechanisms plays an important role in metabolic homeostasis. In addition to mediating 
satiety, afferent vagus nerve fibers, through associated mechanoreceptors, chemoreceptors, 
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and specific metabolite receptors transmit alterations in peripheral levels of metabolic 
molecules, including cholecystokinin, peptide YY, and glucagon-like peptide-1 to the 
brainstem NTS and then these signals reach the hypothalamus and other brain areas [6]. 
Efferent vagus nerve cholinergic output regulates pancreatic insulin and glucagon secretion 
and hepatic gluconeogenesis, the main determinant of fasting blood glucose levels [6]. There 
is also experimental evidence for compromised vagus nerve regulatory function in obesity 
[6,159,160]. In addition, lower vagus nerve activity, determined by heart rate variability 
analysis is documented in autonomic dysfunction reported in obesity, the metabolic 
syndrome and type 2 diabetes [6,161,162]. VNS, a clinically approved approach for treating 
depression and epilepsy has been associated with weight loss, which is more substantial in 
patients with higher degree of obesity [163]. Inflammation in obesity represents an 
important therapeutic target in alleviating insulin resistance and other obesity-related 
complications. Exploring vagus nerve-based cholinergic neurocircuitry in metabolic and 
inflammatory regulation in obesity is an emerging approach that has been experimentally 
tested by using cholinergic modalities, including the acetylcholinesterase inhibitor 
galantamine [164] and α7nAChR agonists [165,166]. Galantamine treatment of mice with 
high fat-induced obesity and the metabolic syndrome prevents further body weight gain and 
significantly decreases glucose and insulin levels and insulin resistance [164]. In addition, 
galantamine lowers leptin, resistin and IL-6 levels and attenuates fatty liver disease in these 
mice [164]. A very recent study significantly substantiated these findings by demonstrating 
the therapeutic anti-inflammatory and disease-alleviating efficacy of galantamine in an 
animal model of type 2 diabetes [167]. These beneficial metabolic and anti-inflammatory 
effects of galantamine, other cholinergic modalities and VNS in experimental settings of 
obesity and type 2 diabetes provide a platform for further exploration of these approaches in 
the treatment of obesity-related disorders [6].
There is a growing interest in inflammation in the context of cancer and especially in solid 
tumors/cancers. Chronic inflammation holds an increased risk of developing cancer. On the 
other hand, oncogene alterations and tumor progression are associated with forming tumor-
associated microenvironment in which immune cells such as tumor associated macrophages 
and T cells, and cytokines and other inflammatory products are active modulators of tumor-
associated angiogenesis, progression and metastases [168]. Therefore, cancer related 
inflammation has been actively studied in the pursuit of identifying new molecular targets 
that can be explored to improve diagnosis and treatment. Implications of neurocircuitry and 
axon guidance molecules, such as netrin-1 in cancer have been indicated [169,170]. A role 
for the vagus nerve in cancer has also been reported. Unilateral cervical vagotomy has been 
shown to promote lung, liver, kidney and adrenal metastases in experimental 4THMpc 
breast carcinoma, suggesting a tonic protective effect of the vagus nerve against metastatic 
disease in this context [171,172]. In line with these observations, higher baseline high 
frequency of heart rate variability, which is indicative for higher vagal tone is associated 
with significantly longer survival of patients with metastatic and recurrent breast cancer 
[173]. Bilateral subdiaphragmatic vagotomy promotes the development of experimental 
carcinogen-induced pancreatic [174] and gastric cancer [175,176]. In contrast to these 
observations, vagotomy has been found to suppress the development of gastric cancer 
through a mechanism involving signaling through M3 mAChRs [177]. Subdiaphragmatic 
Pavlov and Tracey Page 17
Immunol Res. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
vagotomy has been clinically used in the treatment of ulcer. Vagotomy in these settings has 
been associated with increased rate of cancer development and mortality of gastric, 
colorectal, biliary tract, and lung cancer [178–181]. Lower vagal tone (based on heart rate 
variability analysis) is associated with higher risk of 7-day mortality in patients with 
advanced pancreatic and other non-lung cancers [182] and in patients with colorectal, 
pancreatic, prostate, lung and ovarian cancer as compared to healthy individuals [183]. In 
addition to a role in immune and metabolic control, reflex neuronal regulation, involving the 
vagus nerve, of the inflammatory tumor microenvironment has been proposed [184–186]. 
Further studying this regulation and the role of the vagus nerve and other peripheral nerves 
in the complex cancer-inflammation relationship hold significant promises for new 
therapeutic approaches.
7. Translational implications
Ongoing in vitro and in vivo preclinical research has identified neuronal circuits with a role 
in the regulation of immunity and inflammation, characterized cellular and molecular 
mechanisms mediating these pathways and examined the therapeutic efficacy of their 
modulation. Studies translating this insight into clinical settings were also initiated. These 
studies may validate the therapeutic efficacy of new anti-inflammatory compounds, device-
generated neuromodulation or combinations of these two strategies [187].
7.1. Pharmacological interventions
A role for activation of the cholinergic anti-inflammatory pathway by utilizing α7nAChR 
agonists or centrally-acting acetylcholinesterase inhibitors in ameliorating inflammation and 
alleviating disease severity has been shown in various disease models, including septic 
shock, severe sepsis, hemorrhagic shock, rheumatoid arthritis, inflammatory bowel disease, 
obesity and type 2 diabetes [6,70,188]. These preclinical insights have paved the way to 
clinical exploration of these modalities. The anti-inflammatory effects of the α7nAChR 
agonist GTS-21 in doses, previously reported to be safe in humans [189] have been studied 
in human endotoxemia [190]. GTS-21 anti-inflammatory effects have overall been found not 
statistically significant as compared to the placebo-controlled group [190]. However, a 
correlation between higher GTS-21 plasma levels and lower plasma levels of TNF, IL-6 and 
IL-1 receptor agonist has been found [190]. It is an open question whether a higher dose of 
GTS-21 will generate pronounced anti-inflammatory effects. The efficacy of the α7nAChR 
agonist choline has been studied in patients with asthma. Choline treatment significantly 
lowers TNF and other inflammatory markers, suppresses oxidative stress and alleviates 
disease scores [191]. An important new area for clinical studies on the efficacy of α7nAChR 
agonists and galantamine is the spectrum of obesity-driven disorders [6]. An ongoing 
clinical study evaluates the effects of the selective α7nAChR agonist TC-6987 in type 2 
diabetes https://clinicaltrials.gov/ct2/show/NCT01293669?term=Targacept&rank=11). 
Performing clinical trials with galantamine and other centrally-acting acetylcholinesterase 
inhibitors can be facilitated by the abundant clinical database available for these drugs and 
their FDA approval for the symptomatic treatment of Alzheimer’s disease. The efficacy of 
galantamine in doses, which are clinically approved for Alzheimer’s disease, is currently 
being examined in individuals with the metabolic syndrome (https://clinicaltrials.gov/ct2/
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show/NCT02283242?term=cholinergic+obesity&rank=2). Using galantamine and other 
centrally-acting acetylcholinesterase inhibitors with proven efficacy in improving memory 
and cognition might address another important aspect in obesity-driven disorders. These 
diseases and specifically type 2 diabetes are associated with certain degree of cognitive 
dysfunction [140]. Accordingly, the need for prevention or alleviation of this cognitive 
deterioration in strategizing new therapeutic approaches for the treatment of type 2 diabetes 
has been emphasized [140].
7.2. Bioelectronic medicine
The discovery of neuronal circuits in the regulation of immunity and inflammation at the 
Feinstein Institute and other research centers has importantly contributed to the foundation 
of Bioelectronic Medicine. This emerging field focuses on studying neuronal networks that 
target molecular mechanisms of disease, and using neuromodulation by bioelectronic 
devices as treatment. The need for new therapeutic approaches under the umbrella of 
Bioelectronic Medicine is dictated by the lack of efficient pharmaceutical options in the 
treatment of some diseases, significant side effects of currently used drugs, and the 
astronomical cost of some pharmacological remedies. Biolelectronic medicine brings 
together Molecular Medicine, Neuroscience, and Bioengineering. Basic and clinical 
scientists with various background, skills, and different viewpoints are engaged in major 
team efforts to address challenging questions in translating preclinical findings in 
bioelectronic approaches to treat diseases. The use of electricity, i.e. VNS has been pivotal 
in evaluating the therapeutic potential of neuromodulation in preclinical settings of various 
inflammatory and autoimmune disorders, including rheumatoid arthritis. The therapeutic use 
of electricity has a long history. It dates back to Scribonius Largus, the court physician of 
the Roman emperor Claudius. It is intriguing that by using a natural “device”, a live torpedo 
fish as a source of electricity, he was able to treat gout, a form of inflammatory arthritis. If 
we fast-forward to the present, we get to the modern era of utilizing electricity in the 
treatment of rheumatoid arthritis, but this time by electrical VNS through an implanted 
device in a successful clinical trial [7]. This and other ongoing studies with implanted device 
VNS in patients with inflammatory bowel disease (https://clinicaltrials.gov/ct2/show/
NCT02311660?term=vagus+nerve+stimulation&rank=8, https://clinicaltrials.gov/ct2/show/
NCT01569503?term=vagus+nerve+stimulation&rank=7) validate targeted neuromodulation 
in disease treatment. Continuous research efforts focusing on the neuroanatomical and 
functional evaluation of neural networks to target specific molecular mechanisms of disease 
are likely to culminate in new clinical trials. Preclinical research has multiple aspects, 
including neuroanatomical mapping of peripheral organ innervations, determining patterns 
of peripheral autonomic and somatic nerve activity associated with certain disease 
conditions, characterizing the specificity of interaction between nerves and muscle cells, 
glandular cells, immune cells and other types of cells, and elucidating intracellular and 
molecular mechanisms of these interactions. These research efforts go hand in hand with 
developing new technology, including miniaturized devices and electrodes and optogenetic 
methodology suitable for better interrogation of discrete neuronal circuits, imaging systems, 
biocompatible materials, and programs for processing and analyzing large sets of data. The 
therapeutic scope of bioelectronic neuromodulation is not limited to the treatment of 
inflammatory and autoimmune diseases. Continuous progress in evaluating the role of 
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neuronal circuitry in obesity-driven diseases, cancer and other debilitating and life-
threatening disorders and identifying related molecular targets holds a significant promise to 
provide a rationale necessary for designing new therapeutic strategies based on 
neurostimulation or neuroinhibition to treat these diseases.
8. Conclusions and future directions
We have summarized here findings highlighting interactions between the nervous system 
and the immune system. Vagus nerve-mediated and other neural circuits operating on reflex 
principles regulate multiple aspects of immunity and inflammation. On the other hand, 
dysregulated immune activation is associated with altered vagus and other peripheral nerve 
activity and may cause brain neuronal dysfunction. Preclinical research has identified 
several points of the reciprocal nervous system – immune system relationship and its 
intersections with metabolism and behavior that can be explored in new therapeutic 
strategies. Studying the role of cholinergic signaling in neuro-immune interactions in 
various conditions characterized by adverse inflammation has validated the anti-
inflammatory and disease-alleviating properties of α7nAChR agonists, centrally-acting 
acetylcholinesterase inhibitors and M1 mAChR agonists. Clinical testing of some of these 
compounds has also been initiated. In parallel, evaluating the anti-inflammatory efficacy of 
VNS and advanced understanding of neural circuitry controlling inflammation has allowed 
implementation of conceptually novel platforms of disease treatment based on 
neuromodulation within the scope of Bioelectronic Medicine. There is more to learn going 
forward. Continuous research will further elucidate molecular and cellular mechanisms 
underlying neuro-immune interactions and delineate discrete neuronal circuitry that can be 
explored for therapeutic benefit. The current clinical testing of VNS in inflammatory and 
autoimmune disorders promises to be the beginning of the use of bioelectronic technology in 
safe, inexpensive and efficient treatments of a broad spectrum of diseases.
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Fig. 1. The functional anatomy of the inflammatory reflex
Inflammatory mediators, such as cytokines, are released by activated macrophages and other 
immune cells when TLRs and NLRs are activated upon immune challenge. These mediators 
are detected by sensory components of the afferent arm of the inflammatory reflex (red). 
Neuronal interconnections between the NTS, AP, DMN, NA, and higher forebrain regions 
(not shown) integrate afferent signaling and efferent vagus nerve-mediated 
immunoregulatory output. Efferent vagus nerve cholinergic output to the spleen, liver and 
gastrointestinal tract (blue) regulates immune activation and suppresses pro-inflammatory 
cytokine release (dotted red lines). Efferent vagus nerve fibers interact with the splenic 
nerve to suppress pro-inflammatory cytokine release in spleen – a major organ source of 
TNF and other pro-inflammatory cytokines in endotoxemia and other inflammatory 
conditions. This efferent cholinergic arm of the inflammatory reflex is termed the 
cholinergic anti-inflammatory pathway and can be activated in the brain through mAChR-
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mediated mechanisms triggered by M1 mAChR agonists and other mAChR ligands, and 
AChE inhibitors, such as galantamine. Abbreviations: AChE, acetylcholinesterase; AP, area 
postrema; DMN, dorsal motor nucleus of the vagus nerve; LPS, lipopolysaccharide 
(endotoxin); mAChR, muscarinic acetylcholine receptor; NA, nucleus ambiguus; NLRs, 
nucleotide-binding oligomerization domain-like receptors; NTS, nucleus tractus solitarius; 
TLR4, toll-like receptor 4. (Adapted from [6])
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Fig. 2. Peripheral inflammation, autoimmunity and brain function: from sickness behavior to 
neurological complications
The impact of peripheral immune activation with the release of cytokines and other 
inflammatory molecules on the brain is manifested by a spectrum of alterations, known as 
sickness behavior. This is an important adaptive mechanism of brain function in acute 
inflammatory conditions. Peripherally released pro-inflammatory cytokines signal the brain 
through afferent vagus neurons, circumventricular organs, and other mechanisms [8,25,26] 
(not shown). Peripheral inflammation with the release of cytokines also triggers brain pro-
inflammatory signaling, which plays an important mediating role in sickness behavior. Brain 
function alterations and neurological complications are described in numerous inflammatory 
and autoimmune disorders. Dysregulations in neurotransmitter systems, cerebral blood flow 
and microcirculation, brain metabolic activity, and brain pro-inflammatory signaling 
underlie these neurological complications, which can be manifested by cognitive 
deterioration, behavioral derangements and characteristic encephalopaties. These 
neurological conditions can be debilitating and life-threatening and need to be properly 
diagnosed and treated.
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